Get started
Author

Anne M. Favret

Observed names: A Favret, A. Favret, A.M. Favret, Anne Favret, Anne M Favret
Observed institutions: McKesson (United States), Amgen (United States), Montefiore Medical Center, The University of Texas MD Anderson Cancer Center, University of Padua, Tel Aviv University, Sheba Medical Center, Rabin Medical Center, Virginia Oncology Associates, Fred Hutch Cancer Center, Compass Oncology, Sarah Cannon, Highlands Oncology Group, Istituto Oncologico Veneto, Masaryk Memorial Cancer Institute, Dana-Farber Cancer Institute, New York Oncology Hematology, Virginia Cancer Specialists, Duke Medical Center, Tennessee Oncology, Stanford Medicine, Rocky Mountain Cancer Centers, The US Oncology Network, Nebraska Hematology-Oncology, Vanderbilt-Ingram Cancer Center
ORCID: 0000-0002-7917-5238
Observed ORCID: 0000-0002-7917-5238
OpenAlex ID: A5076486609
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
2016 · Gabriel N. Hortobagyi, Salomon M. Stemmer, et al. · New England Journal of Medicine · 2,117
PDF
Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices
2015 · Neelima Denduluri, Debra A. Patt, et al. · Journal of the National Comprehensive Cancer Network · 151
PDF
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study
2013 · Stephen E Jones, Rufus Collea, et al. · The Lancet Oncology · 140
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
2017 · Gabe S. Sonke, Lowell L. Hart, et al. · Breast Cancer Research and Treatment · 91
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)
2024 · Nicholas Turner, Cristina Saura, et al. · Journal of Clinical Oncology · 42
PDF
Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study
2016 · Denise A. Yardley, James Reeves, et al. · Clinical Breast Cancer · 36
Locally Advanced Breast Cancer: Is Surgery Necessary?
2001 · Anne M. Favret, Robert W. Carlson, et al. · The Breast Journal · 31
PDF
First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses.
2018 · Gabriel N. Hortobagyi, Shani Paluch-Shimon, et al. · Journal of Clinical Oncology · 20
Multidisciplinary Management of Locally Advanced Breast Cancer
1999 · Robert W. Carlson, Anne M. Favret · The Breast Journal · 17
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study
2019 · Denise A. Yardley, Lowell Hart, et al. · Clinical Breast Cancer · 16
Dose Intensity in Early-Stage Breast Cancer: A Community Practice Experience
2009 · Robert L. Bretzel, Ralph Cameron, et al. · Journal of Oncology Practice · 13
Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study
2012 · R.P. Collea, F.W. Kruter, et al. · Annals of Oncology · 9
PDF
HER2-Positive Advanced Breast Cancer
2007 · Nicholas J. Robert, Anne M. Favret · Hematology/Oncology Clinics of North America · 9
Everolimus with paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC): A randomized, double-blind, placebo-controlled phase II trial of the Sarah Cannon Research Institute (SCRI).
2012 · Denise Aysel Yardley, Linda D. Bosserman, et al. · Journal of Clinical Oncology · 8
Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC) in MONALEESA-2
2017 · G.S. Sonke, L.L. Hart, et al. · European Journal of Cancer · 6
Maintenance of health-related quality of life in elderly patients treated with ribociclib + letrozole in MONALEESA-2.
2018 · Howard A. Burris, Sara M. Tolaney, et al. · Journal of Clinical Oncology · 4
Abstract GS3-09: Clinical and biomarker subgroup analysis of evERA Breast Cancer: A Phase III trial of giredestrant plus everolimus in patients with estrogen receptor-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor
2026 · H. S. Rugo, S. M. Tolaney, et al. · Clinical Cancer Research · 3
Abstract P5-21-18: Subsequent treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received ribociclib + letrozole vs placebo + letrozole in the phase III MONALEESA-2 study
2018 · KL Blackwell, S Paluch-Shimon, et al. · Cancer Research · 3
Post-progression treatment (tx) analyses of evERA Breast Cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with estrogen receptor–positive, HER2-negative advanced BC (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i).
2026 · Komal L. Jhaveri, Hope S. Rugo, et al. · Journal of Clinical Oncology · 2
Phase Ib/IIa study of RX-5902, a novel orally bioavailable inhibitor of phosphorylated P68, which prevents nuclear β-catenin translocation in patients with triple negative breast cancer
2018 · J.R. Diamond, E. Andreopoulou, et al. · Annals of Oncology · 2
Interim safety results of eribulin (E) combined with ramucirumab (RAM) in patients (pts) with advanced metastatic breast cancer (MBC).
2012 · Denise Aysel Yardley, Cynthia R. C. Osborne, et al. · Journal of Clinical Oncology · 2
Giredestrant plus Everolimus in Advanced Breast Cancer
2026 · Erica L. Mayer, Sara M. Tolaney, et al. · New England Journal of Medicine · 1
PDF
Abstract P5-16-07: Assessment of sacituzumab govitecan (SG) in Black patients (pts) from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)
2022 · Lisa A. Carey, Amelia Zelnak, et al. · Cancer Research · 1
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer
2017 · Joanne L. Blum, Nicholas Robert, et al. · Journal of Clinical Oncology · 1
Abstract P5-21-27: Efficacy and safety of ribociclib plus letrozole in US patients enrolled in the MONALEESA-2 study
2018 · DA Yardley, L Hart, et al. · Cancer Research
Works count: 27
Citation count: 2,725
H-index: 11
I10-index: 11
Year
Topic
Type